Edition:
United States

Cellular Biomedicine Group Inc (CBMG.OQ)

CBMG.OQ on NASDAQ Stock Exchange Global Market

9.65USD
10:53am EDT
Change (% chg)

$0.05 (+0.52%)
Prev Close
$9.60
Open
$9.50
Day's High
$9.70
Day's Low
$9.50
Volume
6,590
Avg. Vol
19,427
52-wk High
$15.61
52-wk Low
$5.15

Latest Key Developments (Source: Significant Developments)

Cellular Biomedicine adds second clinical site in the expansion of CAR-T Phase I clinical trial
Monday, 15 May 2017 06:23am EDT 

May 15 (Reuters) - Cellular Biomedicine Group Inc :Cellular Biomedicine Group (CBMG) announces the addition of a second clinical site in the expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I clinical trial for its CARD-1 trial in patients with non-hodgkin lymphoma (NHL).Cellular Biomedicine Group Inc - on track to share topline clinical data in Q4 of this year as it becomes available from CARD-1 trial.  Full Article

Cellular Biomedicine Q1 net loss per share $0.43
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Cellular Biomedicine Group Inc ::Cellular Biomedicine Group reports first quarter 2017 financial results and provides business highlights.Cellular Biomedicine Group Inc - qtrly net loss per share $ 0.43.Cellular Biomedicine Group Inc - cash and cash equivalents as of march 31, 2017 were $33.4 million compared to $39.3 million as of December 31, 2016.  Full Article

Cellular Biomedicine, GE Healthcare Life Sciences China established strategic research collaboration
Monday, 10 Apr 2017 08:05am EDT 

Cellular Biomedicine Group Inc : Cellular Biomedicine - co, GE Healthcare Life Sciences China established strategic research collaboration .Cellular Biomedicine - collaboration to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.  Full Article

Cellular Biomedicine had working capital of $38.3 mln as of Dec. 31
Tuesday, 14 Mar 2017 06:00am EDT 

Cellular Biomedicine Group Inc : Cellular biomedicine group reports full-year 2016 financial results and recent operational progress .Cellular biomedicine group inc- had working capital of $38.3 million as of december 31, 2016 compared to $13.7 million as of december 31, 2015.  Full Article

Cellular Biomedicine Group announces resale of up to 5.1 mln shares of common stock for sale by selling stockholders
Monday, 20 Jun 2016 05:25pm EDT 

Cellular Biomedicine Group Inc :Resale of up to 5.1 million shares of common stock for sale by the selling stockholders - SEC filing.  Full Article

Cellular Biomedicine reports Q1 results
Monday, 9 May 2016 04:01pm EDT 

Cellular Biomedicine Group Inc : Cellular Biomedicine Group Inc says cash and cash equivalents as of march 31, 2016 were $15.7 million compared to $14.9 million as of december 31, 2015 . Cellular biomedicine group reports first quarter 2016 financial results and provides business highlights .Q1 revenue $488,500 versus $603,400.  Full Article

Cellular Biomedicine Group Inc announces positive 48-week data from phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy
Wednesday, 13 Jan 2016 08:00am EST 

Cellular Biomedicine Group Inc:Announces positive 48-week data from phase IIb Clinical Trial for Knee Osteoarthritis Stem Cell ReJoin Therapy.Says no serious adverse events reported to date.Says 48-week end of study shows primary,secondary endpoints of rejoin therapy group having improved significantly compared to baseline.Says total womac scores as a primary end point show statistical treatment significance at week 48 compared to the baseline.  Full Article

Cellular Biomedicine Group Inc says Wei Cao will not seek renewal of employment contract as CEO
Monday, 11 Jan 2016 09:01am EST 

Cellular Biomedicine Group Inc:Says Wei Cao will not seek renewal of employment contract as CEO.Says committee of board has been established to oversee the professional recruitment of a new chief executive officer.Tony Liu, will assume full responsibilities as the interim chief executive officer.  Full Article